News Center

• Sep. 23

  2022

  “LENALIDOMIDE CAPSULES” OBTAINS DRUG REGISTRATION APPROVAL

  “Lenalidomide Capsules (25mg)"developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

• Sep. 21

  2022

  CSPC Selected as China's Top 10 Innovative BigPharma Companies

  On September 16, 2022, Menet held an online launch event for its "Innovation Leads Future-2021 China's Top 100 Innovative Biopharma Companies" list. CSPC was selected as one of China's Top 10 Innovative BigPharma Companies, among the top three.

• Sep. 19

  2022

  CSPC Selected as One of “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022”

  Recently, renowned pharmaceutical media “Healthcare Executive” published the list of “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022". CSPC is once again among the first tier of the list.

• Sep. 13

  2022

  “TG103 INJECTION” OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

  “TG103 Injection”, a class 1 biological innovative drug of the Group, has been granted approval by the National Medical Products Administration of the PRC to conduct clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) in China.

• Sep. 13

  2022

  “TG103 INJECTION” OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE

  “TG103 Injection”, a class 1 biological innovative drug of the Group, has been granted approval by the National Medical Products Administration of the PRC to conduct clinical trials for the treatment of Alzheimer’s disease (AD) in China.

• Sep. 05

  2022

  CSPC Again Ranked in Brand Finance China 500

  “Brand Finance China 500 2022" was released. CSPC has been included in the list for the second time.